Hidradenitis suppurativa responding to treatment with infliximab
Identifieur interne : 000A46 ( Istex/Checkpoint ); précédent : 000A45; suivant : 000A47Hidradenitis suppurativa responding to treatment with infliximab
Auteurs : Anita Lasocki ; Rodney Sinclair ; Peter Foley [Australie] ; Helen Saunders [Australie]Source :
- Australasian Journal of Dermatology [ 0004-8380 ] ; 2010-08.
Abstract
A series of four cases of severe recalcitrant hidradenitis suppurativa treated with infliximab is presented. All patients had failed to respond to prior medical and surgical management. Baseline Quantiferon‐TB Gold and chest radiograph were carried out before commencement of treatment. No patients had associated Crohn's disease. All patients received induction infusions of infliximab 5 mg/kg at weeks 0, 2 and 6, followed by eight weekly maintenance infusions. The total number of infusions varied between 4 and 6. Skin photography with Sartorius scoring was used to evaluate response to treatment. All patients experienced marked improvement in their disease activity, with a mean 48% improvement in Sartorius score after one infusion (week 2, P < 0.01), and 70% improvement after three infusions (week 14, P < 0.01). Time to relapse following cessation of therapy ranged from 6 weeks to 4 months. Further studies examining the efficacy of infliximab and its effect on the course of the disease, particularly relating to long‐term management, are required.
Url:
DOI: 10.1111/j.1440-0960.2010.00623.x
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
ISTEX:1B98309E8BFA2D9A7426D7B4DABDB5EC9507B7FCLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hidradenitis suppurativa responding to treatment with infliximab</title><author><name sortKey="Lasocki, Anita" sort="Lasocki, Anita" uniqKey="Lasocki A" first="Anita" last="Lasocki">Anita Lasocki</name></author><author><name sortKey="Sinclair, Rodney" sort="Sinclair, Rodney" uniqKey="Sinclair R" first="Rodney" last="Sinclair">Rodney Sinclair</name></author><author><name sortKey="Foley, Peter" sort="Foley, Peter" uniqKey="Foley P" first="Peter" last="Foley">Peter Foley</name></author><author><name sortKey="Saunders, Helen" sort="Saunders, Helen" uniqKey="Saunders H" first="Helen" last="Saunders">Helen Saunders</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1B98309E8BFA2D9A7426D7B4DABDB5EC9507B7FC</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1111/j.1440-0960.2010.00623.x</idno><idno type="url">https://api.istex.fr/document/1B98309E8BFA2D9A7426D7B4DABDB5EC9507B7FC/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000C90</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000C90</idno><idno type="wicri:Area/Istex/Curation">000C90</idno><idno type="wicri:Area/Istex/Checkpoint">000A46</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000A46</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Hidradenitis suppurativa responding to treatment with infliximab</title><author><name sortKey="Lasocki, Anita" sort="Lasocki, Anita" uniqKey="Lasocki A" first="Anita" last="Lasocki">Anita Lasocki</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Sinclair, Rodney" sort="Sinclair, Rodney" uniqKey="Sinclair R" first="Rodney" last="Sinclair">Rodney Sinclair</name><affiliation></affiliation><affiliation><wicri:noCountry code="subField">and</wicri:noCountry></affiliation></author><author><name sortKey="Foley, Peter" sort="Foley, Peter" uniqKey="Foley P" first="Peter" last="Foley">Peter Foley</name><affiliation></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Skin and Cancer Foundation, Fitzroy, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Saunders, Helen" sort="Saunders, Helen" uniqKey="Saunders H" first="Helen" last="Saunders">Helen Saunders</name><affiliation></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Skin and Cancer Foundation, Fitzroy, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Australie</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Australasian Journal of Dermatology</title><title level="j" type="alt">AUSTRALASIAN JOURNAL DERMATOLOGY</title><idno type="ISSN">0004-8380</idno><idno type="eISSN">1440-0960</idno><imprint><biblScope unit="vol">51</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="186">186</biblScope><biblScope unit="page" to="190">190</biblScope><biblScope unit="page-count">5</biblScope><publisher>Blackwell Publishing Asia</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2010-08">2010-08</date></imprint><idno type="ISSN">0004-8380</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0004-8380</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A series of four cases of severe recalcitrant hidradenitis suppurativa treated with infliximab is presented. All patients had failed to respond to prior medical and surgical management. Baseline Quantiferon‐TB Gold and chest radiograph were carried out before commencement of treatment. No patients had associated Crohn's disease. All patients received induction infusions of infliximab 5 mg/kg at weeks 0, 2 and 6, followed by eight weekly maintenance infusions. The total number of infusions varied between 4 and 6. Skin photography with Sartorius scoring was used to evaluate response to treatment. All patients experienced marked improvement in their disease activity, with a mean 48% improvement in Sartorius score after one infusion (week 2, P < 0.01), and 70% improvement after three infusions (week 14, P < 0.01). Time to relapse following cessation of therapy ranged from 6 weeks to 4 months. Further studies examining the efficacy of infliximab and its effect on the course of the disease, particularly relating to long‐term management, are required.</div></front></TEI><affiliations><list><country><li>Australie</li></country></list><tree><noCountry><name sortKey="Lasocki, Anita" sort="Lasocki, Anita" uniqKey="Lasocki A" first="Anita" last="Lasocki">Anita Lasocki</name><name sortKey="Sinclair, Rodney" sort="Sinclair, Rodney" uniqKey="Sinclair R" first="Rodney" last="Sinclair">Rodney Sinclair</name></noCountry><country name="Australie"><noRegion><name sortKey="Foley, Peter" sort="Foley, Peter" uniqKey="Foley P" first="Peter" last="Foley">Peter Foley</name></noRegion><name sortKey="Saunders, Helen" sort="Saunders, Helen" uniqKey="Saunders H" first="Helen" last="Saunders">Helen Saunders</name><name sortKey="Saunders, Helen" sort="Saunders, Helen" uniqKey="Saunders H" first="Helen" last="Saunders">Helen Saunders</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Istex/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A46 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd -nk 000A46 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Istex
|étape= Checkpoint
|type= RBID
|clé= ISTEX:1B98309E8BFA2D9A7426D7B4DABDB5EC9507B7FC
|texte= Hidradenitis suppurativa responding to treatment with infliximab
}}
| This area was generated with Dilib version V0.6.31. |  |